Biocompatible peritoneal dialysis solutions: Do we have one?

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 4, 2010, Pages 723-732

  Chaudhary, Kunal ^a   Khanna, Ramesh ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'BALANCE'; AMINO ACID; BICARBONATE; BICAVERA; DIALYSIS FLUID; GAMBROSOL TRIO; GLUCOSE; ICODEXTRIN; LACTIC ACID; NUTRINEAL; PHYSIONEAL; POLYMER; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; DIALYSIS MEMBRANE; HUMAN; OUTCOMES RESEARCH; PATIENT SAFETY; PERITONEAL DIALYSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARDIOVASCULAR SYSTEM; DIALYSIS SOLUTIONS; EVIDENCE-BASED MEDICINE; GLUCOSE; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEUM; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950937491     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05720809     Document Type: Review

References (92)

1. Popovich R, Moncreif J, Nolph K: Continuous ambulatory peritoneal dialysis. Artif Organs 2: 84-86, 1978 (Pubitemid 10250328)
2. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470-479, 2002 (Pubitemid 34106290)
3. Ha H, Yu MR, Choi HN, Cha MK, Kang HS, Kim MH, Lee HB: Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 20: S10-S18, 2000 (Pubitemid 32184346)
4. Witowski J, Jorres A, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Bender TO, Passlick-Deetjen J, Breborowicz A: Glucose degradation products in peritoneal dialysis fluids: Do they harm? Kidney Int 84: S148-S151, 2003 (Pubitemid 36513398)
5. Krediet RT, Zweers MM, vander Wal AC, Struijk DJ: Neo-angiogenesis in the peritoneal membrane. Perit Dial Int 20: S19-S25, 2000
6. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK: Changing prescribing practice in CAPD patients in Korea: Increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21: 2893-2899, 2006
7. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK: Superior patient survival for CAPD patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (BALANCE). Perit Dial Int 25: 248-255, 2005 (Pubitemid 40724205)
8. Gotloib L, Bar-Sella P, Shostak A: Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 5: 212-215, 1985
9. Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Acute and long term changes observed in imprints of mouse mesothelium exposed to glucose-enriched lactate buffered dialysis solution. Nephron 70: 466-477, 1995
10. Gotloib L, Shostak A, Wajsbrot V, Kushnier R: High glucose induces an hypertrophic, senescent mesothelial cell phenotype after long, in vivo exposure. Nephron 82: 164-173, 1999 (Pubitemid 29263976)
11. Breborowicz A, Polubinska A, Oreopoulos DG: Changes in volume of peritoneal mesothelial cells exposed to osmotic stress. Perit Dial Int 19: 119-123, 1999 (Pubitemid 30088061)
12. Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Effects of hyperosmolarity upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution. Nephron 81: 301-309, 1999 (Pubitemid 29101456)
13. Gotloib L, Wajsbrot V, Shostak A: Osmotic agents hamper mesothelial repopulation as seen in the doughnut in vivo model. Perit Dial Int 25: S26-S30, 2005 (Pubitemid 40883210)
14. Ishibashi Y, Sugimoto T, Ichikawa Y, Akatsuka A, Miyata T, Nangaku M, Tagawa H, Kurokawa K: Glucose dialysate induces mitochondrial DNA damage in peritoneal mesothelial cells. Perit. Dial Int 22: 11-21, 2002 (Pubitemid 34326574)
15. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, Craig KJ, Williams JD, Topley N: Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 64: 1854-1866, 2003 (Pubitemid 37323717)
16. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 14: 1541-1549, 1999 (Pubitemid 29241752)
17. Topley N, Kaur D, Petersen MM, Jörres A, Williams JD, Faict D, Holmes CJ: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis fluids on mesothelial and neutrophil function. J Am Soc Nephrol 7: 218-224, 1996 (Pubitemid 26092471)
18. Wajsbrot V, Shostak A, Gotloib L, Kushnier R: Biocompatibility of a glucose-free, acidic lactated solution for peritoneal dialysis evaluated by population analysis of mesothelium. Nephron 79: 322-332, 1998 (Pubitemid 28310339)
19. Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fussholler A, Schneider M, Grabensee B: Peritoneal dialysis fluids with a physiological pH based on either lactate or bicarbonate: Effects on human mesothelial cells. Am J Kidney Dis 38: 867-875, 2001 (Pubitemid 32927914)
20. Liberek T, Topley N, Jorres A, Petersen MM, Coles GA, Gahl GM, Williams JD: Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 65: 260-265, 1993 (Pubitemid 23268036)
21. Zareie M, Keuning ED, ter Wee PM, Schalkwijk CG, Beelen RH, van den Born J: Improved biocompatibility of bicar-bonate-lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 21:208-216, 2006 (Pubitemid 43057132)
22. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Krediet RT: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 19: 517-525, 1999
23. Krediet RT, Lindholm B, Rippe B: Pathophysiology of peritoneal membrane failure. Perit Dial Int 20[suppl 4]: S22-S42, 2000
24. Parikova A, Smit W, Struijk DG, Krediet RT: Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 70: 1988-1994, 2006 (Pubitemid 44863388)
25. Mactier R, Khanna R, Twardowski Z, Nolph K: Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 80: 1311-1316, 1987 (Pubitemid 18027772)
26. Heimburger O, Waniewski J, Werynski A, Sun Park M, Lindholm B: Lymphatic absorption in CAPD patients with loss of ultrafiltration capacity. Blood Purif 13: 327-339, 1995 (Pubitemid 26021518)
27. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible patho-physiological role in CAPD. Kidney Int 51: 182-186, 1997 (Pubitemid 27064536)
28. Fussholder A, zurNieden S, Grabensee B, Plum J: Peritoneal fluid and solute transport: Influence on treatment time, peritoneal dialysis modality and peritonitis incidence. J Am Soc Nephrol 13: 1055-1060, 2002 (Pubitemid 34274103)
29. Shostak A, Wajbrost V, Gotolib L: High Glucose accelerates the life cycle of the in vivo exposed mesothelium. Kidney Int 58: 2044-2052, 2000
30. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol May 12: 1046-1051, 2001 (Pubitemid 32378346)
31. Davies SJ: Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 66: 2437-2445, 2004
32. Kim DJ, Oh DJ, Kim B. Lim YH, Kang WH, Lee BH, Lee SK, Huh W, Kim SE, Lee MK, Kang SA, Oh HY: The effect of continuous peritoneal dialysis on change in seum leptin. Perit Dial Int 19: S172-S175, 1999 (Pubitemid 30015471)
33. Teta D, Tedjani A, Burnier, M Bevington A, Brown J, Harris K: Glucose containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes. Nephrol Dial Transplant 20: 1329-1335, 2005 (Pubitemid 41430606)
34. Delarue J, Maingourd C: Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 37: S103-S107, 2001 (Pubitemid 32048034)
35. Fernstrom A, Hylander B, Moritz A, Jacobson H, Rossner S: Increase in intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 18: 166-171, 1998 (Pubitemid 28221298)
36. Selby NM, Fonsesca S, Hulme H, Fluck RJ, Tall MW, McIntyre CW: Hypertonic glucose based peritoneal dialysis is associated with higher blood pressure and adverse hemodynamics as compared with icodextrin. Nephrol Dial Transplant 20: 1848-1853, 2005
37. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ: Mortality risks for peritoneal dialysis and hemodialysis. Am J Kidney Dis 34: 1065-1074, 1999
38. Vonesh EF, Moran J: Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 10: 354-365, 1999 (Pubitemid 29068076)
39. Peers E, Gokal R: Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 22: 8-12, 1998 (Pubitemid 28068862)
40. Mistry CD, Gokal R, Peers E: A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperos-molar glucose solutions in CAPD. MIDAS study group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46: 496-503, 1994
41. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA: Assesement of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The dextrin in APD in Amsterdam (DIANA) group. Perit Dial Int 20: S106-S113, 2000
42. Woodrow G, Stables G, Oldroyd B, Gibson J, Turney JH, Brownjohn AM: Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dialysis Transplant 14: 1530-1535, 1999 (Pubitemid 29241750)
43. Finkelstein F, Healey H, Abu-alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 16: 546-554, 2005 (Pubitemid 41725153)
44. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, Donker AJ: Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24 hr dialysate creatinine clearance. Nephrol Dial Transplant 12: 550-553, 1997 (Pubitemid 27105633)
45. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Ro-drigues-Carmona A, Vychityl A, Macnamara E, Ekstrand A, Tranaeus A, Filho JC; EAPOS Group: Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67:1609-1615, 2005 (Pubitemid 40463142)
46. Davies SJ, Woodrow G, Donovan K, Plum G, Williams P, Johansson AC, Bosselmann HP, Heimbürger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double blind randomized controlled trial. JAm Soc Nephrol 14: 2338-2344, 2003 (Pubitemid 37052381)
47. Adachi Y, NakagawaY, Nishio A: Icodextrin preserves residual renal function in patients with automated peritoneal dialysis. Perit Dial Int 26: 405-407, 2006 (Pubitemid 44340011)
48. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM: Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 15: 862-866, 2000 (Pubitemid 30312008)
49. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM: Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 63: 1556-1563, 2003 (Pubitemid 36350022)
50. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R: Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 21: 275-281, 2001
51. Babazono T, Nakamoto H, Kasai K, Kuriyama S, Sugimoto T, Nakayama M, Hamada C, Furuya R, Hasegawa H, Kasahara M, Moriishi M, Tomo T, Miyazaki M, Sato M, Yorioka N, Kawaguchi Y; Japanese Extraneal Collaborated Study Group: Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 27: 409-415, 2007
52. Gursu EM, Ozdemir A, Yalinbas B, Gürsu RU, Canbakan M: The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol 66: 263-268, 2006 (Pubitemid 44541213)
53. Canbakan M, Sahin GM: Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail 29: 289-293, 2007 (Pubitemid 46752341)
54. Paniagua R, Ventura MD, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MD, García-González Z, Villanueva D, Orihuela O, Prado-Uribe MD, Alcántara G, Amato D: Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 29: 422-432, 2009
55. Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV: Glucose-free dialysis solutions: Inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 25: 453-460, 2005 (Pubitemid 41448400)
56. Lin W, Chen YC, Wu MS, Hsu HJ, Sun CY, Lin YK, Wu IW: Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients. Ren Fail 31: 98-105, 2009
57. Moriishi M, Kawanishi H, Watanabe H, Tsuchiya S: Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv Perit Dial 21: 21-24, 2005
58. Davies SJ, Garcia Lopez E, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Lindholm B, Tranaeus A, Divino Filho JC: Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 23: 2982-2988, 2008
59. van Hoeck KJ, Rusthoven E, Vermeylen L, Vandesompel A, Marescau B: Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to nocturnal intermittent peritoneal dialysis (NIPD) in children. Nephrol Dial Transplant 18: 1383-1387, 2003 (Pubitemid 36826961)
60. Plum J Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B: An amino acid based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: An intraindividual randomized study. Perit Dial Int 19: 418-428, 1999 (Pubitemid 30015427)
61. Park MS, Heimbürger O, Bergström J, Waniewski J, Werynski A, Lindholm B: Peritoneal transport during dialysis with amino-acid based solutions. Perit Dial Int 13: 280-288, 1993 (Pubitemid 23302110)
62. Kopple JD, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink LD, Martis L, Boyle CA, Serkes KD, Vonesh E, Jones MR: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47: 1148-1157, 1995
63. Jones MR, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz R, Knight T, Kraus Jr A, McDonald L, Hartnett M, Weaver M, Martis L, Moran J: Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 32: 760-769, 1998 (Pubitemid 28516306)
64. Taylor GS, Patel V, Spencer S, Fluck RJ, Mclntyre CW: Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 58: 445-450, 2002 (Pubitemid 35446916)
65. Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, Chan TM: A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 42: 173-183, 2003
66. Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van Egmond AM, Fieren MW, Swart R: Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. JAmSoc Nephrol 16: 1486-1493, 2005 (Pubitemid 41716534)
67. Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Kahriman D, van der Steen J, Hop WC, Swart R, Fieren MW: Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2: 74-80, 2007 (Pubitemid 351178097)
68. Brulez HF, van Guldener C, Donker AJ, ter Wee PM: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 14: 154-159, 1999 (Pubitemid 29041886)
69. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA: Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal. Perit Dial Int 17: 279-286, 1997 (Pubitemid 27470497)
70. Yang SY, Huang JW, Shih KY, Hsu SP, Chu PL, Chu TS, Wu KD: Factors associated with increased plasma homo-cysteine in patients using an amino acid peritoneal dialysis fluid. Nephrol Dial Transplant 20: 161-166, 2005
71. Chan TM, Leung JK, Sun Y, Lai KN, Tsang RC, Yung S:Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function. Nephrol Dial Transplant 18: 1086-1094, 2003 (Pubitemid 36722508)
72. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS: Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 66: 1257-1265, 2004 (Pubitemid 39121036)
73. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL, Faict D, Degréve B, Tangelder GJ, Beelen RH, van den Born J: Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 25: 58-67, 2005 (Pubitemid 40378498)
74. Veech RL: The untoward effect of the anions of dialysis fluids. Kidney Int 34: 587-597, 1988
75. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer F: Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 14: 2632-2638, 2003 (Pubitemid 37169350)
76. Theodoridis M, Passadakis P, Kriki P, Gioka T, Panagoutsos S, Mourvati E, Thodis E, Kantartzi K, Vargemezis V: The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability. Ren Fail 30: 161-167, 2008 (Pubitemid 351311475)
77. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, Lindholm B: Short-term effects of a new bicarbonate/lac-tate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: A randomized controlled study. Perit Dial Int 28: 44-52, 2008 (Pubitemid 351566125)
78. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, Kim BS, Park HC, Choi KH, Ha SK, Han DS, Lee HY: The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: An open randomized prospective trial. Perit Dial Int 28: 174-182, 2008
79. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischet-srieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418, 2004 (Pubitemid 38870119)
80. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 22: 552-559, 2007
81. Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, Detmer A: Bicarbonate-versus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int 12: 281-286, 1992
82. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Grontoft KC, Larsson R, Berglund J, Tranaeus AP, Faict D: Bicarbonate and bicarbon ate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 53: 1061-1067, 1998 (Pubitemid 28155684)
83. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Fried-berg M, Wieslander A: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59: 348-357, 2001 (Pubitemid 32055244)
84. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG: Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: A prospective, crossover single-dwell study. Perit Dial Int 28: 35-43, 2008 (Pubitemid 351566124)
85. Montenegro J, Saracho RM, Martinez IM, Mupoz RI, Ocharan JJ, Valladares E: Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 26: 89-94, 2006 (Pubitemid 44339667)
86. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM: Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: A randomized crossover study. Adv Perit Dial 20: 170-176, 2004
87. Marshall J, Jennings P, Scott A, Fluck RJ, Mcintyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). KidneyInt 64: 1480-1486, 2003 (Pubitemid 37153816)
88. Moist LM, Port FK, Orzol SM Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11: 556-564, 2000 (Pubitemid 30115086)
89. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT; NECOSAD Study Group: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62: 1046-1053, 2002 (Pubitemid 35316736)
90. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, Chuang HF, Hung KY, Wu KD, Tsai TJ: Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 24: 2909-2914, 2009
91. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: A 1-year study. Nephrol Dial Transplant 24: 2899-2908, 2009
92. Davies Simon J: Preserving residual renal function in peritoneal dialysis: Volume or biocompatibility? Nephrol Dial Transplant 24: 2620-2622, 2009